Article
Cardiac & Cardiovascular Systems
Hiddo J. L. Heerspink, C. David Sjostrom, Niels Jongs, Glenn M. Chertow, Mikhail Kosiborod, Fan Fan Hou, John J. McMurray, Peter Rossing, Ricardo Correa-Rotter, Raisa Kurlyandskaya, Bergur Stefansson, Robert D. Toto, Anna Maria Langkilde, David C. Wheeler
Summary: Dapagliflozin significantly reduces all-cause mortality in CKD patients, predominantly by reducing non-cardiovascular deaths. The benefits are consistent across pre-specified subgroups and driven largely by reductions in deaths due to infections and malignancies.
EUROPEAN HEART JOURNAL
(2021)
Article
Endocrinology & Metabolism
Yutaka Seino, Kohei Kaku, Takashi Kadowaki, Taro Okamoto, Asako Sato, Masayoshi Shirakawa, Edward A. O'Neill, Samuel S. Engel, Keith D. Kaufman
Summary: In Japanese patients with type 2 diabetes, adding sitagliptin to ipragliflozin monotherapy provided significant improvement in glycemic control and was generally well tolerated.
DIABETES OBESITY & METABOLISM
(2021)
Article
Endocrinology & Metabolism
Masaru Kitazawa, Takashi Katagiri, Hiromi Suzuki, Satoshi Matsunaga, Mayuko Yamada, Tomoo Ikarashi, Masahiko Yamamoto, Kazuo Furukawa, Midori Iwanaga, Mariko Hatta, Kazuya Fujihara, Takaho Yamada, Shiro Tanaka, Hirohito Sone
Summary: This study compared the long-term efficacy of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors as second-line drugs in patients not at high risk of ASCVD. The results showed no significant difference in achieving the primary endpoint at 52 weeks, but sitagliptin had a higher HbA1c reduction rate at 24 weeks.
DIABETES OBESITY & METABOLISM
(2021)
Review
Endocrinology & Metabolism
Yu Jiang, Pingping Yang, Linghua Fu, Lizhe Sun, Wen Shen, Qinghua Wu
Summary: A network meta-analysis suggests that empagliflozin may be superior to other SGLT2 inhibitors in reducing the risks of all-cause mortality and cardiovascular events in patients with type 2 diabetes mellitus.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Endocrinology & Metabolism
Mauro Rigato, Gian Paolo Fadini, Angelo Avogaro
Summary: This study aimed to assess the safety of SGLT2 inhibitors (SGLT2is) in elderly patients with type 2 diabetes. A meta-analysis of randomized controlled trials (RCTs) showed that SGLT2is were well tolerated in the elderly, but older patients were underrepresented in clinical trials.
DIABETES OBESITY & METABOLISM
(2023)
Review
Cardiac & Cardiovascular Systems
Edoardo Mannucci, Lara Naletto, Gabriele Vaccaro, Antonio Silverii, Ilaria Dicembrini, Basilio Pintaudi, Matteo Monami
Summary: This network meta-analysis compares the effects of glucose-lowering drugs on various aspects such as glucose control, body weight, quality of life, and adverse events. The results suggest that different drugs have varying effects on HbA1c at different time points, with some showing better efficacy in the short term and others performing better in the long term.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
(2021)
Article
Cardiac & Cardiovascular Systems
Xuexun Li, Qian Zhang, Lingming Zhu, Guangqiang Wang, Peipei Ge, Aizhen Hu, Xuerong Sun
Summary: SGLT2 inhibitors have shown to improve cardiovascular and renal outcomes in patients with heart failure, regardless of the presence or absence of diabetes. They also contribute to a lower incidence of serious adverse events, although an increased risk of volume depletion was observed.
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2021)
Review
Immunology
Panagiotis Theofilis, Marios Sagris, Evangelos Oikonomou, Alexios S. Antonopoulos, Gerasimos Siasos, Konstantinos Tsioufis, Dimitris Tousoulis
Summary: This study conducted a systematic review and meta-analysis to assess the effect of SGLT2 inhibition on inflammatory markers in animal models. The findings suggest that SGLT2 inhibition results in reduction of inflammatory markers, further validating the suggested anti-inflammatory mechanism of action.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Review
Cardiac & Cardiovascular Systems
Zinan Zhao, Pengfei Jin, Yatong Zhang, Xin Hu, Chao Tian, Deping Liu
Summary: This study investigated the effect of SGLT2 inhibitors in patients with diabetes with CVD or at high cardiovascular risk. The results showed benefits on CV death/HHF, HHF, renal composite outcomes, and HbA1c reduction with SGLT2 inhibitors. The reduction of renal composite outcomes was observed in patients without a history of HF.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Cardiac & Cardiovascular Systems
Naoto Katakami, Tomoya Mita, Hidenori Yoshii, Toshihiko Shiraiwa, Tetsuyuki Yasuda, Yosuke Okada, Keiichi Torimoto, Yutaka Umayahara, Hideaki Kaneto, Takeshi Osonoi, Tsunehiko Yamamoto, Nobuichi Kuribayashi, Kazuhisa Maeda, Hiroki Yokoyama, Keisuke Kosugi, Kentaro Ohtoshi, Isao Hayashi, Satoru Sumitani, Mamiko Tsugawa, Kayoko Ryomoto, Hideki Taki, Tadashi Nakamura, Satoshi Kawashima, Yasunori Sato, Hirotaka Watada, Iichiro Shimomura
Summary: The study evaluated the effects of tofogliflozin on brachial-ankle pulse wave velocity in patients with type 2 diabetes without a history of apparent cardiovascular disease. Tofogliflozin significantly inhibited the increased baPWV, suggesting that it suppressed the progression of arterial stiffness in these patients.
CARDIOVASCULAR DIABETOLOGY
(2021)
Review
Endocrinology & Metabolism
Yuichiro Mori, O. Kenrik Duru, Katherine R. Tuttle, Shingo Fukuma, Daisuke Taura, Norio Harada, Nobuya Inagaki, Kosuke Inoue
Summary: This systematic review and meta-analysis investigated the effectiveness of SGLT2 inhibitors in preventing new-onset diabetes. The results showed that SGLT2 inhibitors were associated with a reduced risk of new-onset diabetes.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Review
Endocrinology & Metabolism
Ioannis Avgerinos, Thomas Karagiannis, Panagiota Kakotrichi, Theodoros Michailidis, Aris Liakos, David R. Matthews, Apostolos Tsapas, Eleni Bekiari
Summary: Sotagliflozin demonstrates efficacy in reducing blood glucose, body weight, and systolic blood pressure in patients with type 2 diabetes, with beneficial effects on heart failure and myocardial infarction. Its overall safety profile is comparable with other sodium-glucose cotransporter-2 inhibitors.
DIABETES OBESITY & METABOLISM
(2022)
Article
Endocrinology & Metabolism
Surya Panicker Rajeev, Carl Alexander Roberts, Emily Brown, Victoria S. Sprung, Jo A. Harrold, Jason C. G. Halford, Andrej Stancak, Emma J. Boyland, Graham J. Kemp, Julie Perry, Elaine Howarth, Richard Jackson, Andrew Wiemken, Richard Schwab, Daniel J. Cuthbertson, John P. H. Wilding
Summary: This study evaluated the impact of dapagliflozin on food intake, eating behavior, energy expenditure, brain response to food cues, and body composition in patients with type 2 diabetes mellitus. The results showed that dapagliflozin reduced glycated hemoglobin and body weight, but did not affect food intake or energy expenditure.
DIABETES OBESITY & METABOLISM
(2023)
Article
Endocrinology & Metabolism
Hiddo J. L. Heerspink, Priya Vart, Niels Jongs, Brendon L. Neuen, George Bakris, Brian Claggett, Muthiah Vaduganathan, Finnian McCausland, Kieran F. Docherty, Pardeep S. Jhund, Scott D. Solomon, Vlado Perkovic, John J. V. McMurray
Summary: The combination treatment of SGLT2 inhibitors and MRA in patients with type 2 diabetes and CKD can significantly extend event-free survival and overall survival, with an estimated gain of 6.7 years in event-free survival compared to ACE inhibitors/angiotensin receptor blockers. This conclusion is supported by both trial data and observational study results. Even in a conservative scenario, the combination therapy still provides a substantial gain of 2.5 years in event-free survival.
DIABETES OBESITY & METABOLISM
(2023)
Article
Endocrinology & Metabolism
Kirsten Thiele, Matthias Rau, Niels-Ulrik K. Hartmann, Julia Moellmann, Joachim Jankowski, Michael Boehm, Andras P. Keszei, Nikolaus Marx, Michael Lehrke
Summary: SGLT2 inhibitors have been shown to reduce hospitalization for heart failure and cardiovascular mortality, for both patients with and without type 2 diabetes mellitus. These agents have been found to increase haemoglobin and haematocrit levels, which may be a predictor of their cardiovascular benefits.
DIABETES OBESITY & METABOLISM
(2021)
Article
Neurosciences
Huilong Yuan, Shuai Ouyang, Runan Yang, Shunhua Li, Yingxin Gong, Lifang Zou, Tianyu Jia, Shanhong Zhao, Bing Wu, Zhihua Yi, Hui Liu, Liran Shi, Lin Li, Yun Gao, Guilin Li, Hong Xu, Shuangmei Liu, Chunping Zhang, Shangdong Liang
BRAIN RESEARCH BULLETIN
(2018)
Article
Neurosciences
Yingxin Gong, Yanhong Zhou, Jingjian Yang, Shunhua Li, Zilin Wang, Jingan Rao, Lin Li, Huilong Yuan, Liran Shi, Runan Yang, Xiumei Xu, Shuangmei Liu, Shangdong Liang, Lifang Zou
BRAIN RESEARCH BULLETIN
(2019)
Review
Behavioral Sciences
Zilin Wang, Zhiwen Luo, Shunhua Li
EPILEPSY & BEHAVIOR
(2019)
Review
Endocrinology & Metabolism
Shunhua Li, Lu Ding, Xinhua Xiao
Summary: In patients with T2DM, LCDs are more effective than LFDs in improving HbA1c and reducing body weight, with some benefits for cardiovascular risk factors in longer-term diabetes management, although the effect of weight loss diminishes over time.
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY
(2021)
Article
Nutrition & Dietetics
Liyuan Zhou, Shunhua Li, Qian Zhang, Miao Yu, Xinhua Xiao
Summary: Detrimental exposures in mothers are recognized as risk factors for metabolic dysfunction in offspring. Maternal exercise has been reported as an effective strategy to maintain offspring health. This study showed that maternal exercise can combat the adverse effects of maternal high-fat diet on metabolism in adult offspring, and miRNAs play a role in mediating this protective effect.
FRONTIERS IN NUTRITION
(2022)
Article
Nutrition & Dietetics
Lu Ding, Jieying Liu, Liyuan Zhou, Xinmiao Jia, Shunhua Li, Qian Zhang, Miao Yu, Xinhua Xiao
Summary: The study found that a high-fat diet affects the circadian rhythms in the liver and adipose tissue of gestational mice, as well as the diurnal rhythm of gut microbiota. It also showed that the high-fat diet leads to obesity and worsens metabolic functions in gestational mice.
FRONTIERS IN NUTRITION
(2022)
Article
Biochemistry & Molecular Biology
Shunhua Li, Liyuan Zhou, Qian Zhang, Miao Yu, Xinhua Xiao
Summary: Genistein has beneficial effects on glucose metabolism and adipose tissue browning, which may be achieved through alterations in gut microbiota. Depleting gut microbiota abolishes these benefits.
Article
Integrative & Complementary Medicine
Li Shun-Hua, Li Lin, Yang Ru-Nan, Liang Shang-Dong
CHINESE JOURNAL OF NATURAL MEDICINES
(2020)